These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 25855708)

  • 21. The Role of Risk-Reducing Surgery in Hereditary Breast and Ovarian Cancer.
    Hartmann LC; Lindor NM
    N Engl J Med; 2016 Feb; 374(5):454-68. PubMed ID: 26840135
    [No Abstract]   [Full Text] [Related]  

  • 22. The STAR trial: evidence for raloxifene as a breast cancer risk reduction agent for postmenopausal women.
    Bevers TB
    J Natl Compr Canc Netw; 2007 Sep; 5(8):719-24. PubMed ID: 17927929
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Task force cautious about chemoprevention. Official guidelines are out about taking tamoxifen and raloxifene to prevent breast cancer. These drugs can help, but they aren't for everyone.
    Harv Womens Health Watch; 2002 Oct; 10(2):1-2. PubMed ID: 12393316
    [No Abstract]   [Full Text] [Related]  

  • 24. Tamoxifen and risk of contralateral breast cancer among women with inherited mutations in BRCA1 and BRCA2: a meta-analysis.
    Xu L; Zhao Y; Chen Z; Wang Y; Chen L; Wang S
    Breast Cancer; 2015 Jul; 22(4):327-34. PubMed ID: 26022977
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chemoprevention of breast cancer.
    Dalton RR; Kallab AM
    South Med J; 2001 Jan; 94(1):7-15. PubMed ID: 11213947
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Variability in Cancer Risk with BRCA Mutations.
    Cancer Discov; 2015 Jul; 5(7):OF16. PubMed ID: 25952264
    [No Abstract]   [Full Text] [Related]  

  • 27. Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.
    Metcalfe K; Lynch HT; Foulkes WD; Tung N; Kim-Sing C; Olopade OI; Eisen A; Rosen B; Snyder C; Gershman S; Sun P; Narod SA
    JAMA Oncol; 2015 Jun; 1(3):306-13. PubMed ID: 26181175
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparing breast cancer risk assessment models.
    Gail MH; Mai PL
    J Natl Cancer Inst; 2010 May; 102(10):665-8. PubMed ID: 20427429
    [No Abstract]   [Full Text] [Related]  

  • 29. Effect of prevention strategies on survival and quality-adjusted survival of women with BRCA1/2 mutations: an updated decision analysis.
    Grann VR; Jacobson JS; Thomason D; Hershman D; Heitjan DF; Neugut AI
    J Clin Oncol; 2002 May; 20(10):2520-9. PubMed ID: 12011131
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chemoprevention in postmenopausal women.
    Rastogi P
    Menopause; 2008; 15(4 Suppl):810-5. PubMed ID: 18596603
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Methods of surgical prevention of breast cancer and of ovarian cancer in BRCA mutation carriers].
    Bit-Sava EM; Belogurova MB; Imianitov EN; Balandov SG; Korniushin OV; Borisov MK
    Vopr Onkol; 2013; 59(2):5-11. PubMed ID: 23814843
    [No Abstract]   [Full Text] [Related]  

  • 32. [Genetic testing in patients at risk for carcinoma of the breast].
    Kiechle M
    Dtsch Med Wochenschr; 2006 Oct; 131(43):2420-2. PubMed ID: 17054060
    [No Abstract]   [Full Text] [Related]  

  • 33. Population-Wide Screening for Germline BRCA1 and BRCA2 Mutations: Too Much of a Good Thing?
    Yurgelun MB; Hiller E; Garber JE
    J Clin Oncol; 2015 Oct; 33(28):3092-5. PubMed ID: 26282646
    [No Abstract]   [Full Text] [Related]  

  • 34. Chemoprevention of breast cancer.
    O'Regan RM
    Cancer Treat Res; 2000; 103():183-207. PubMed ID: 10948447
    [No Abstract]   [Full Text] [Related]  

  • 35. Tamoxifen, hormone receptors and hormone replacement therapy in women previously treated for breast cancer: a cohort study.
    Dew JE; Wren BG; Eden JA
    Climacteric; 2002 Jun; 5(2):151-5. PubMed ID: 12051110
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Breast cancer and duration of tamoxifen.
    Prescrire Int; 2015 Sep; 24(163):220. PubMed ID: 26417636
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetic risk assessment and prevention: the role of genetic testing panels in breast cancer.
    Lerner-Ellis J; Khalouei S; Sopik V; Narod SA
    Expert Rev Anticancer Ther; 2015; 15(11):1315-26. PubMed ID: 26523341
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
    Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
    Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevention of breast cancer in women who carry BRCA1 or BRCA2 mutations: a critical review of the literature.
    Calderon-Margalit R; Paltiel O
    Int J Cancer; 2004 Nov; 112(3):357-64. PubMed ID: 15382059
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Soy and breast cancer: the controversy continues.
    Martínez ME; Thomson CA; Smith-Warner SA
    J Natl Cancer Inst; 2006 Apr; 98(7):430-1. PubMed ID: 16595771
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.